Belosalik ointment for outside. approx. 15g

Release form

Ointment for external use.

pharmachologic effect

A drug with anti-inflammatory, antipruritic, antiproliferative, antimicrobial and keratolytic action for external use.

Betamethasone has anti-inflammatory, anti-allergic, anti-proliferative and antipruritic effects.

When applied to the surface of the skin, betamethasone has a quick and strong effect in the focus of inflammation, reducing the severity of objective symptoms (erythema, edema, lichenification) and subjective sensations (itching, irritation, pain).

Salicylic acid, due to its keratolytic action, cleans the affected areas from scales, promotes the penetration of betamethasone into the skin, maintains the acidic environment of the skin, preventing the development of bacterial and fungal infections.

Indications

Subacute and chronic dermatoses, in which therapy with topical corticosteroids is effective, and accompanied by hyperkeratosis and desquamation, including:

- Psoriasis.

- Eczema (dyshidrotic, seborrheic, tylotic).

- Neurodermatitis.

- Lichen planus.

- Asbestosis.

- Chronic discoid lupus erythematosus.

- Ichthyosis and ichthyosis skin lesions.

- Seborrhea.

- Seborrheic dermatitis (scalp).

The drug in the form of a solution for external use is indicated for use on the scalp, as well as in children 6 months of age and older.

Contraindications

- Tuberculosis of the skin.

- Cutaneous manifestations of syphilis.

- Chickenpox.

- Viral skin infections.

- Skin post-vaccination reactions.

- Open wounds.

- Trophic ulcers.

- Rosacea.

- Acne vulgaris.

- Children up to age 6 months (for ointment).

- Hypersensitivity to betamethasone, salicylic acid or to any of the auxiliary components of the drug.

Application during pregnancy and lactation

The use of the drug Belosalik (in the form of an ointment and / or solution for external use) in pregnant women is allowed in cases where the intended benefit to the mother outweighs the risk to the fetus.

In such cases, the use of the drug should be short-lived and limited to small areas of the skin.

During the period of breastfeeding, the use of the drug Belosalik is possible according to strict indications, but the drug should not be applied to the skin of the breast before feeding.

special instructions

The ointment is intended for external use only on the skin and / or scalp.

Avoid getting the ointment in the eyes and on the mucous membranes.

Long-term use of the ointment on the skin of the face is not recommended due to the possible development of dermatitis like rosacea, perioral dermatitis, skin atrophy and acne.

Avoid using the drug in the anogenital area.

It is not recommended to use the drug under an occlusive dressing, except when necessary.

With the development of fungal or bacterial microflora on the skin, additional use of an antibacterial or antifungal agent is necessary.

Use in pediatrics

The use of the drug Belosalik in children should be as short as possible, subject to strict precautions.

in children, there is a danger of systemic absorption of a proportionally larger amount of active components due to the predominance of the area of ��the skin over the body weight and insufficient maturity of the epidermis.

Do not use the drug in children under bandages and, especially under plasticized diapers, which may increase the risk of adverse events.

Influence on the ability to drive vehicles and control mechanisms There is no data on the adverse effects of Belosalik on the ability to drive vehicles and mechanisms.

Structure

1 g of ointment contains:

Active substances: betamethasone

Name ENG

BELOSALIC LOTION

Clinical and pharmacological group

Drug with anti-inflammatory and keratolytic action for external use

ATX code

Betamethasone in combination with other drugs

Dosage

0.05% + 3% x 15g

Structure

1 g of ointment contains: Active substances: betamethasone dipropionate - 640 mcg, which corresponds to the content of betamethasone - 500 mcg

salicylic acid 30 mg.

Excipients: mineral oil, petroleum jelly

Storage conditions and periods

At a temperature not higher than 25 degrees.

Expiration date: 4 years

INN / Active ingredient

salicylic acid, betamethasone

Specifications

Category

Psoriasis

Scope of the drug

Leather

Release form

Ointment

Manufacturer country

Croatia

Package quantity, pcs

one

Minimum age from

6 months

Way of introduction

Locally

,

On the skin

,

Outwardly

Vacation conditions

Without recipe

Brand name

Belupo

The amount of the dosage form in the primary package

15 g

Primary packaging type

Tuba

Type of consumer packaging

Pack of cardboard

Anatomical and therapeutic characteristics

D07XC01 Betamethasone, in combination with other drugs

Dosage form

Ointment for external use

The target audience

Children

Expiration date in days

1460

Package weight, g

25

Mode of application

:

The drug is intended for external use.

< br> < br> A small amount of ointment is evenly distributed over the surface of the skin, rubbing lightly.

Frequency rate of application - 2 times / day, in mild cases, a single use is sufficient.

< br> The duration of a continuous course of treatment is usually limited to 3-4 weeks.

If a longer course of therapy is required, it is recommended to use the drug less often, for example, every other day.

In the treatment of chronic diseases, treatment should be continued for some time after the disappearance of all symptoms, under the supervision of a doctor, in order to avoid a relapse of the disease.

< br> < br> Repeated courses of therapy are possible during the year

Pharmaco-therapeutic group

:

Topical glucocorticosteroid + keratolytic agent

Dosage (volume) of the substance in the preparation

:

1 g of solution contains: < br> < br> Active substances: betamethasone dipropionate - 640 mcg, which corresponds to the content of betamethasone - 500 mcg

salicylic acid - 20 mg.

Information on technical characteristics, delivery set, country of manufacture